HNF4A and metabolic dysfunction-associated steatotic liver disease: We are suggesting that hepatic HNF4α inhibition can attenuate bile acid toxicity and be more effective as a therapeutic strategy in NAFLD patients; however, it is necessary to study the optimal timing of HNF4α inhibition due to the worsening of hepatic steatosis.